Market Overview

Wedbush Raises TESARO Price Target From $107 To $139

Share:
Wedbush Raises TESARO Price Target From $107 To $139
Related TSRO
Wall Street's M&A Chatter From July 13: Tesaro, Time, Frontier Communications, First Citizens BancShares, Brink's-Maco Transportadora
Mid-Afternoon Market Update: Crude Oil Up 1%; DragonWave Shares Plunge

Wedbush Securities reiterated its Outperform rating and raised its price target on TESARO Inc (NASDAQ: TSRO) shares to $139 from $107 as it "sees the clinical benefit of niraparib in HRD-negative patients as likely leading to approval in the entire platinum-sensitive ovarian market."

Waltham, Massachusetts-based TESARO, has an approved product in Varubi (rolapitant) for the prevention of delayed nausea and vomiting associated with emetogenic chemotherapy. The company is also developing its Phase 3 asset, niraparib, a PARP inhibitor in ovarian and breast cancer indications.

TESARO said it would file NDA and MAA for all patients with recurrent, platinum-sensitive ovarian cancer in the fourth quarter 2016.

"[W]e see the lack of requirement for a companion diagnostic for niraparib in these patients as a potential advantage over competing PARP inhibitors," analyst David Nierengarten wrote in a note.

Related Link: 16 Stocks Moving In Monday's Pre-Market Session

Nierengarten, who expects niraparib to be launched in the United States in mid-2017, now assumes 50 percent peak penetration into the platinum-sensitive market (up from 20 percent) and cuts peak penetration into the platinum-resistant market to 15 percent from a previous 25 percent.

"These changes raise our 2021 niraparib sales estimate to $2.2 billion (from $1.6 billion), which also includes revenues from metastatic breast cancer gBRCAmut patients," Nierengarten highlighted.

The analyst says 50 percent peak market share is achievable given the favorable comparison of niraparib with data from olaparib-treated patients and olaparib being limited to gBRCA patients only.

Nierengarten also noted niraparib has first-mover advantage in this treatment setting versus rucaparib.

"Underwhelming data from rucaparib in the third line setting presented at ESMO gives us greater confidence that niraparib will be the market leader in the earlier line of therapy, especially if a companion diagnostic is required," the analyst added.

Shares of Tesaro closed Friday's regular trading at $99.26. In the pre-market hours Monday, they gained 9.82 percent to $109.01 and near its 52-week high of $110.48.

Full ratings data available on Benzinga Pro.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Latest Ratings for TSRO

DateFirmActionFromTo
May 2017OppenheimerInitiates Coverage OnOutperform
Apr 2017PiperJaffrayInitiates Coverage OnOverweight
Mar 2017WedbushReiteratesOutperform

View More Analyst Ratings for TSRO
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas News Health Care Price Target Reiteration Analyst Ratings Best of Benzinga

 

Related Articles (TSRO)

View Comments and Join the Discussion!